BioNTech SE (BNTX) Stock Forecast, Price Target & Predictions
BNTX Stock Forecast
BioNTech SE stock forecast is as follows: an average price target of $156.86 (represents a 43.95% upside from BNTX’s last price of $108.97) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.
BNTX Price Target
The average price target for BioNTech SE (BNTX) is $156.86 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $359.00 to $81.00. This represents a potential 43.95% upside from BNTX's last price of $108.97.
BNTX Analyst Ratings
According to 16 Wall Street analysts, BioNTech SE's rating consensus is 'Buy'. The analyst rating breakdown for BNTX stock is 0 'Strong Buy' (0.00%), 12 'Buy' (75.00%), 2 'Hold' (12.50%), 2 'Sell' (12.50%), and 0 'Strong Sell' (0.00%).
BioNTech SE Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Terence Flynn | Morgan Stanley | $145.00 | $113.05 | 28.26% | 33.06% |
| Sep 17, 2024 | Akash Tewari | Jefferies | $150.00 | $123.97 | 21.00% | 37.65% |
| Sep 16, 2024 | Tazeen Ahmad | Bank of America Securities | $150.00 | $123.40 | 21.56% | 37.65% |
| Sep 13, 2024 | Akash Tewari | Jefferies | $96.00 | $105.00 | -8.57% | -11.90% |
| Aug 06, 2024 | Emmanuel Papadakis | Deutsche Bank | $95.00 | $79.50 | 19.50% | -12.82% |
| Aug 05, 2024 | Terence Flynn | Morgan Stanley | $93.00 | $78.36 | 18.68% | -14.66% |
| Aug 02, 2024 | Yifeng Liu | HSBC | $101.00 | $82.01 | 23.16% | -7.31% |
| Jun 26, 2024 | Raghuram Selvaraju | H.C. Wainwright | $113.00 | $82.52 | 36.94% | 3.70% |
| May 13, 2024 | Cory Kasimov | Evercore ISI | $100.00 | $92.72 | 7.85% | -8.23% |
| May 07, 2024 | Etzer Darout | BMO Capital | $122.00 | $91.53 | 33.29% | 11.96% |
The latest BioNTech SE stock forecast, released on Sep 23, 2024 by Terence Flynn from Morgan Stanley, set a price target of $145.00, which represents a 28.26% increase from the stock price at the time of the forecast ($113.05), and a 33.06% increase from BNTX last price ($108.97).
BioNTech SE Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 6 | 14 |
| Avg Price Target | - | $121.50 | $117.14 |
| Last Closing Price | $108.97 | $108.97 | $108.97 |
| Upside/Downside | -100.00% | 11.50% | 7.50% |
In the current month, the average price target of BioNTech SE stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to BioNTech SE's last price of $108.97. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 21, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Oct 21, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 07, 2024 | UBS | Buy | Buy | Hold |
| Sep 23, 2024 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| Sep 19, 2024 | Deutsche Bank | Buy | Buy | Hold |
| Sep 18, 2024 | UBS | Neutral | Neutral | Hold |
| Sep 16, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Sep 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 16, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Sep 13, 2024 | Jefferies | Buy | Buy | Hold |
BioNTech SE's last stock rating was published by Cowen & Co. on Oct 21, 2024. The company gave BNTX a "Hold" rating, the same as its previous rate.
BioNTech SE Financial Forecast
BioNTech SE Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $1.28B | $4.28B | $3.46B | $3.20B | $6.37B | $5.53B | $6.09B | $5.31B | $2.05B | $345.44M | $67.46M | $41.76M | $27.66M | $28.66M |
| Avg Forecast | $1.78B | $696.39M | $219.90M | $289.98M | $1.95B | $599.32M | $144.58M | $479.46M | $2.03B | $899.06M | $685.12M | $1.15B | $3.91B | $2.02B | $4.07B | $4.80B | $4.45B | $5.90B | $3.86B | $1.71B | $232.24M | $60.40M | $95.00M | $26.52M | $34.04M |
| High Forecast | $1.78B | $696.39M | $219.90M | $289.98M | $1.95B | $1.18B | $144.58M | $484.96M | $3.01B | $919.39M | $685.12M | $1.15B | $3.91B | $2.02B | $4.07B | $4.80B | $4.45B | $5.90B | $3.86B | $1.71B | $232.24M | $60.40M | $95.00M | $26.52M | $40.84M |
| Low Forecast | $1.78B | $696.39M | $219.90M | $289.98M | $1.95B | $187.46M | $144.58M | $473.96M | $1.67B | $878.72M | $685.12M | $1.15B | $3.91B | $2.02B | $4.07B | $4.80B | $4.45B | $5.90B | $3.86B | $1.71B | $232.24M | $60.40M | $95.00M | $26.52M | $27.23M |
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 20 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.11% | 1.09% | 1.71% | 0.79% | 1.33% | 1.24% | 1.03% | 1.38% | 1.19% | 1.49% | 1.12% | 0.44% | 1.04% | 0.84% |
BioNTech SE's average Quarter revenue forecast for Jun 23 based on 5 analysts is $685.12M, with a low forecast of $685.12M, and a high forecast of $685.12M. BNTX's average Quarter revenue forecast represents a -46.35% decrease compared to the company's last Quarter revenue of $1.28B (Mar 23).
BioNTech SE EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 20 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $840.60M | $3.36B | $2.26B | $1.96B | $4.72B | $4.74B | $4.69B | $4.04B | $1.66B | $194.28M | $-177.11M | $-71.94M | $-44.27M | $-21.09M |
| Avg Forecast | $271.54M | $105.95M | $33.45M | $44.12M | $296.82M | $91.18M | $22.00M | $72.94M | $308.48M | $136.78M | $104.23M | $175.00M | $594.95M | $307.89M | $619.29M | $2.55B | $677.58M | $898.33M | $586.82M | $1.06B | $35.33M | $9.19M | $-316.70M | $4.03M | $-25.14M |
| High Forecast | $271.54M | $105.95M | $33.45M | $44.12M | $296.82M | $179.06M | $22.00M | $73.78M | $458.19M | $139.87M | $104.23M | $175.00M | $594.95M | $307.89M | $619.29M | $3.06B | $677.58M | $898.33M | $586.82M | $1.27B | $35.33M | $9.19M | $-253.36M | $4.03M | $-20.11M |
| Low Forecast | $271.54M | $105.95M | $33.45M | $44.12M | $296.82M | $28.52M | $22.00M | $72.11M | $254.04M | $133.69M | $104.23M | $175.00M | $594.95M | $307.89M | $619.29M | $2.04B | $677.58M | $898.33M | $586.82M | $844.18M | $35.33M | $9.19M | $-380.04M | $4.03M | $-30.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 4.80% | 5.65% | 7.35% | 3.16% | 1.85% | 7.00% | 5.22% | 6.88% | 1.57% | 5.50% | -19.28% | 0.23% | -10.97% | 0.84% |
5 analysts predict BNTX's average Quarter EBITDA for Jun 23 to be $104.23M, with a high of $104.23M and a low of $104.23M. This is -87.60% lower than BioNTech SE's previous annual EBITDA (Mar 23) of $840.60M.
BioNTech SE Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 20 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $502.20M | $2.28B | $1.78B | $1.67B | $3.70B | $3.17B | $3.21B | $2.79B | $1.13B | $366.91M | $-210.03M | $-88.30M | $-53.39M | $-30.10M |
| Avg Forecast | $277.95M | $-288.38M | $-552.65M | $-410.97M | $707.74M | $-347.51M | $-480.03M | $-296.75M | $566.25M | $-140.64M | $-198.15M | $62.80M | $1.84B | $815.93M | $1.69B | $1.87B | $1.77B | $2.50B | $1.79B | $718.84M | $-40.72M | $-90.17M | $-344.35M | $-58.69M | $-35.75M |
| High Forecast | $277.95M | $-288.38M | $-552.65M | $-410.97M | $707.74M | $198.58M | $-480.03M | $-296.75M | $705.66M | $-140.64M | $-198.15M | $62.80M | $1.84B | $815.93M | $1.69B | $2.24B | $1.77B | $2.50B | $1.79B | $862.61M | $-40.72M | $-90.17M | $-275.48M | $-58.69M | $-28.60M |
| Low Forecast | $277.95M | $-288.38M | $-552.65M | $-410.97M | $707.74M | $-1.02B | $-480.03M | $-296.75M | $420.39M | $-140.64M | $-198.15M | $62.80M | $1.84B | $815.93M | $1.69B | $1.49B | $1.77B | $2.50B | $1.79B | $575.08M | $-40.72M | $-90.17M | $-413.23M | $-58.69M | $-42.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 8.00% | 1.24% | 2.19% | 0.99% | 1.98% | 1.79% | 1.29% | 1.56% | 1.57% | -9.01% | 2.33% | 0.26% | 0.91% | 0.84% |
BioNTech SE's average Quarter net income forecast for Jun 23 is $-198.15M, with a range of $-198.15M to $-198.15M. BNTX's average Quarter net income forecast represents a -139.46% decrease compared to the company's last Quarter net income of $502.20M (Mar 23).
BioNTech SE SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 20 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $131.60M | $137.50M | $153.80M | $148.10M | $105.10M | $145.90M | $76.90M | $59.80M | $47.60M | $35.66M | $27.59M | $20.25M | $15.20M | $11.25M |
| Avg Forecast | $292.59M | $114.16M | $36.05M | $47.54M | $319.82M | $98.25M | $23.70M | $78.60M | $332.39M | $147.38M | $112.31M | $188.57M | $641.07M | $331.76M | $667.29M | $53.05M | $730.10M | $967.96M | $632.31M | $30.33M | $38.07M | $9.90M | $78.97M | $4.35M | $13.36M |
| High Forecast | $292.59M | $114.16M | $36.05M | $47.54M | $319.82M | $192.94M | $23.70M | $79.50M | $493.70M | $150.71M | $112.31M | $188.57M | $641.07M | $331.76M | $667.29M | $63.66M | $730.10M | $967.96M | $632.31M | $36.40M | $38.07M | $9.90M | $94.76M | $4.35M | $16.03M |
| Low Forecast | $292.59M | $114.16M | $36.05M | $47.54M | $319.82M | $30.73M | $23.70M | $77.70M | $273.73M | $144.05M | $112.31M | $188.57M | $641.07M | $331.76M | $667.29M | $42.44M | $730.10M | $967.96M | $632.31M | $24.27M | $38.07M | $9.90M | $63.17M | $4.35M | $10.69M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.70% | 0.21% | 0.46% | 0.22% | 1.98% | 0.20% | 0.08% | 0.09% | 1.57% | 0.94% | 2.79% | 0.26% | 3.50% | 0.84% |
BioNTech SE's average Quarter SG&A projection for Jun 23 is $112.31M, based on 5 Wall Street analysts, with a range of $112.31M to $112.31M. The forecast indicates a -14.66% fall compared to BNTX last annual SG&A of $131.60M (Mar 23).
BioNTech SE EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 20 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $2.07 | $9.38 | $7.43 | $6.86 | $15.13 | $12.98 | $13.24 | $11.42 | $4.64 | $1.56 | $-0.88 | $-0.38 | $-0.24 | $-0.13 |
| Avg Forecast | $1.17 | $-1.21 | $-2.32 | $-1.73 | $2.98 | $-1.46 | $-2.02 | $-1.25 | $2.38 | $-0.59 | $-0.83 | $0.26 | $7.74 | $3.43 | $7.09 | $9.16 | $7.46 | $10.51 | $7.54 | $2.94 | $-0.17 | $-0.38 | $-0.06 | $-0.25 | $-0.17 |
| High Forecast | $1.17 | $-1.21 | $-2.32 | $-1.73 | $2.98 | $0.84 | $-2.02 | $-1.25 | $2.97 | $-0.59 | $-0.83 | $0.26 | $7.74 | $3.43 | $7.09 | $9.16 | $7.46 | $10.51 | $7.54 | $2.94 | $-0.17 | $-0.38 | $-0.06 | $-0.25 | $-0.14 |
| Low Forecast | $1.17 | $-1.21 | $-2.32 | $-1.73 | $2.98 | $-4.28 | $-2.02 | $-1.25 | $1.77 | $-0.59 | $-0.83 | $0.26 | $7.74 | $3.43 | $7.09 | $9.16 | $7.46 | $10.51 | $7.54 | $2.94 | $-0.17 | $-0.38 | $-0.06 | $-0.25 | $-0.21 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 7.84% | 1.21% | 2.16% | 0.97% | 1.65% | 1.74% | 1.26% | 1.52% | 1.58% | -9.11% | 2.32% | 6.61% | 0.97% | 0.75% |
According to 5 Wall Street analysts, BioNTech SE's projected average Quarter EPS for Jun 23 is $-0.83, with a low estimate of $-0.83 and a high estimate of $-0.83. This represents a -140.27% decrease compared to BNTX previous annual EPS of $2.07 (Mar 23).
BioNTech SE Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.63 | $70.00 | 11011.11% | Buy |
| ELEV | Elevation Oncology | $0.52 | $9.00 | 1630.77% | Buy |
| NVAX | Novavax | $9.12 | $58.00 | 535.96% | Buy |
| CRSP | CRISPR Therapeutics | $50.59 | $109.58 | 116.60% | Buy |
| IOVA | Iovance Biotherapeutics | $11.44 | $21.00 | 83.57% | Buy |
| BNTX | BioNTech SE | $108.97 | $156.86 | 43.95% | Buy |
| SRPT | Sarepta Therapeutics | $123.07 | $169.63 | 37.83% | Buy |
| PTCT | PTC Therapeutics | $40.39 | $46.50 | 15.13% | Hold |
| KRYS | Krystal Biotech | $170.85 | $191.00 | 11.79% | Buy |
| DNA | Ginkgo Bioworks | $7.63 | $7.34 | -3.80% | Buy |
| MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
BNTX Forecast FAQ
Is BioNTech SE a good buy?
Yes, according to 16 Wall Street analysts, BioNTech SE (BNTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 75.00% of BNTX's total ratings.
What is BNTX's price target?
BioNTech SE (BNTX) average price target is $156.86 with a range of $81 to $359, implying a 43.95% from its last price of $108.97. The data is based on 16 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will BioNTech SE stock go up soon?
According to Wall Street analysts' prediction for BNTX stock, the company can go up by 43.95% (from the last price of $108.97 to the average price target of $156.86), up by 229.45% based on the highest stock price target, and down by -25.67% based on the lowest stock price target.
Can BioNTech SE stock reach $200?
BNTX's highest twelve months analyst stock price target of $359 supports the claim that BioNTech SE can reach $200 in the near future.
What are BioNTech SE's analysts' financial forecasts?
BioNTech SE's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $3.17B (high $3.76B, low $2.76B), average EBITDA is $482.93M (high $571.66M, low $419.44M), average net income is $-417M (high $129.54M, low $-1.087B), average SG&A $520.37M (high $615.97M, low $451.95M), and average EPS is $-1.752 (high $0.545, low $-4.571). BNTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.99B (high $2.99B, low $2.99B), average EBITDA is $455.06M (high $455.06M, low $455.06M), average net income is $-974M (high $-974M, low $-974M), average SG&A $490.33M (high $490.33M, low $490.33M), and average EPS is $-4.097 (high $-4.097, low $-4.097).
Did the BNTX's actual financial results beat the analysts' financial forecasts?
Based on BioNTech SE's last annual report (Dec 2022), the company's revenue was $17.31B, beating the average analysts forecast of $14.8B by 16.93%. Apple's EBITDA was $13.1B, beating the average prediction of $4.07B by 221.69%. The company's net income was $9.43B, beating the average estimation of $6.21B by 51.96%. Apple's SG&A was $544.2M, missing the average forecast of $1.69B by -67.86%. Lastly, the company's EPS was $38.78, beating the average prediction of $27.42 by 41.43%. In terms of the last quarterly report (Mar 2023), BioNTech SE's revenue was $1.28B, beating the average analysts' forecast of $1.15B by 11.01%. The company's EBITDA was $840.6M, beating the average prediction of $175M by 380.34%. BioNTech SE's net income was $502.2M, beating the average estimation of $62.8M by 699.68%. The company's SG&A was $131.6M, missing the average forecast of $188.57M by -30.21%. Lastly, the company's EPS was $2.07, beating the average prediction of $0.264 by 683.59%